Brokerages Set Oculis Holding AG (NASDAQ:OCS) Target Price at $29.29

Oculis Holding AG (NASDAQ:OCS) has been given an average rating of “Buy” by the nine ratings firms that are currently covering the company, Marketbeat Ratings reports. Nine research analysts have rated the stock with a buy recommendation. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $29.29.

A number of research firms recently issued reports on OCS. Robert W. Baird lowered their target price on Oculis from $64.00 to $35.00 and set an “outperform” rating on the stock in a report on Tuesday, March 19th. Chardan Capital reiterated a “buy” rating and issued a $30.00 price target on shares of Oculis in a research report on Tuesday, March 19th. HC Wainwright reiterated a “buy” rating and issued a $29.00 price target on shares of Oculis in a research report on Thursday, February 29th. Finally, Wedbush reiterated an “outperform” rating and issued a $29.00 price target on shares of Oculis in a research report on Wednesday, March 6th.

Oculis Price Performance

NASDAQ:OCS opened at $12.03 on Tuesday. The business’s 50-day moving average price is $11.97 and its 200 day moving average price is $11.20. Oculis has a 52-week low of $9.05 and a 52-week high of $14.50. The company has a quick ratio of 5.29, a current ratio of 5.29 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS) last released its earnings results on Monday, March 18th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.04. The firm had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.28 million. As a group, sell-side analysts predict that Oculis will post -1.75 EPS for the current fiscal year.

Institutional Investors Weigh In On Oculis

A number of institutional investors have recently bought and sold shares of the business. abrdn plc acquired a new stake in Oculis during the 4th quarter worth about $15,980,000. Compagnie Lombard Odier SCmA boosted its position in Oculis by 47.3% during the 4th quarter. Compagnie Lombard Odier SCmA now owns 95,750 shares of the company’s stock worth $1,053,000 after acquiring an additional 30,750 shares during the period. HRT Financial LP acquired a new stake in Oculis during the 1st quarter worth about $178,000. Ergoteles LLC acquired a new stake in Oculis during the 2nd quarter worth about $247,000. Finally, Searle & CO. acquired a new stake in shares of Oculis during the 4th quarter valued at about $112,000. 22.30% of the stock is currently owned by institutional investors and hedge funds.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.